2-Cyclohexylideneacetic acid → N-(3-tert-butylpyrazolo[1,5-a]pyrimidin-2-yl)-2-cyclohexylideneacetamide
반응식
[C:1]([C:5]1[C:6]([NH2:14])=[N:7][N:8]2[CH:13]=[CH:12][CH:11]=[N:10][C:9]=12)([CH3:4])([CH3:3])[CH3:2].[C:15]1(=[CH:21][C:22](O)=[O:23])[CH2:20][CH2:19][CH2:18][CH2:17][CH2:16]1>>[C:1]([C:5]1[C:6]([NH:14][C:22](=[O:23])[CH:21]=[C:15]2[CH2:20][CH2:19][CH2:18][CH2:17][CH2:16]2)=[N:7][N:8]2[CH:13]=[CH:12][CH:11]=[N:10][C:9]=12)([CH3:4])([CH3:2])[CH3:3]참가 물질
3
실험 절차
The product from Example 105B and 2-cyclohexylideneacetic acid were processed using the method analogous to that described in Example 137 to afford the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.44 (s, 9H), 1.50-1.63 (m, 6H), 2.15-2.18 (m, 2H), 2.80-2.82 (m, 2H), 5.80 (br s, 1H), 6.98 (dd, J=6.8, 4.1 Hz, 1H), 8.48 (dd, J=4.1, 2.0 Hz, 1H), 8.91 (dd, J=7.1, 1.7 Hz, 1H), 9.58 (br s, 1H); MS (DCI) m/z 313 (M+H)+.
출처 및 근거
- ORD 기록
- ord-ba2a614f52be4f9cae11d9c54690e7d7
- 출처 데이터셋
- uspto-grants-2013_12